Cephalon Receives FDA Approval to Market Sugar-Free Formulation of ACTIQ(R).
Cephalon Inc. announced that it has received an approval letter from the U.S. Food and Drug Administration to market a new sugar-free formulation of ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The sugar-free formulation, which is bioequivalent to the currently available product, will be marketed for the same indication as ACTIQ using the same name.
